JP2023518340A - 鼻腔内ｍＲＮＡワクチン - Google Patents

鼻腔内ｍＲＮＡワクチン Download PDF

Info

Publication number
JP2023518340A
JP2023518340A JP2022548838A JP2022548838A JP2023518340A JP 2023518340 A JP2023518340 A JP 2023518340A JP 2022548838 A JP2022548838 A JP 2022548838A JP 2022548838 A JP2022548838 A JP 2022548838A JP 2023518340 A JP2023518340 A JP 2023518340A
Authority
JP
Japan
Prior art keywords
mrna
combination
mrna molecules
vaccine
antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022548838A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518340A5 (https=
Inventor
ティエスト，ウィム
フーリック，ダイアン ヴァン
Original Assignee
イーザアールエヌーエー イムノセラピーズ エンヴェー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーザアールエヌーエー イムノセラピーズ エンヴェー filed Critical イーザアールエヌーエー イムノセラピーズ エンヴェー
Publication of JP2023518340A publication Critical patent/JP2023518340A/ja
Publication of JP2023518340A5 publication Critical patent/JP2023518340A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001138—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/35—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022548838A 2020-02-14 2021-02-15 鼻腔内ｍＲＮＡワクチン Pending JP2023518340A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20157300 2020-02-14
EP20157300.3 2020-02-14
PCT/EP2021/053633 WO2021160881A1 (en) 2020-02-14 2021-02-15 Intranasal mrna vaccines

Publications (2)

Publication Number Publication Date
JP2023518340A true JP2023518340A (ja) 2023-05-01
JP2023518340A5 JP2023518340A5 (https=) 2024-01-25

Family

ID=69593570

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022548838A Pending JP2023518340A (ja) 2020-02-14 2021-02-15 鼻腔内ｍＲＮＡワクチン

Country Status (13)

Country Link
US (1) US20230071518A1 (https=)
EP (1) EP4103226A1 (https=)
JP (1) JP2023518340A (https=)
KR (1) KR20230004447A (https=)
CN (1) CN115443148B (https=)
AU (1) AU2021219304A1 (https=)
BR (1) BR112022015666A2 (https=)
CA (1) CA3170239A1 (https=)
IL (1) IL295507A (https=)
MX (1) MX2022009943A (https=)
TW (1) TW202144002A (https=)
WO (1) WO2021160881A1 (https=)
ZA (1) ZA202209779B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11814464B2 (en) 2019-04-29 2023-11-14 Yale University Poly(amine-co-ester) polymers and polyplexes with modified end groups and methods of use thereof
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
AU2021293780A1 (en) 2020-06-19 2023-02-02 Yale University Poly(amine-co-ester) polymers with modified end groups and enhanced pulmonary delivery
US11918643B2 (en) 2020-12-22 2024-03-05 CureVac SE RNA vaccine against SARS-CoV-2 variants
WO2023037320A1 (en) * 2021-09-10 2023-03-16 Intron Biotechnology, Inc. Mucosal messenger rna vaccine
JP2024545093A (ja) * 2021-12-08 2024-12-05 イェール ユニバーシティー 細胞および組織に標的化するためのポリ（アミン－ｃｏ－エステル）ナノ粒子への表面コンジュゲーション
EP4608442A1 (en) 2022-10-28 2025-09-03 GlaxoSmithKline Biologicals S.A. Nucleic acid based vaccine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016537978A (ja) * 2013-11-12 2016-12-08 ヴリジェ ユニヴェルシテ ブリュッセル Ｒｎａ転写ベクター及びその使用
JP2017513956A (ja) * 2014-04-23 2017-06-01 モデルナティーエックス， インコーポレイテッド 核酸ワクチン
WO2019141814A1 (en) * 2018-01-18 2019-07-25 Etherna Immunotherapies Nv Lipid nanoparticles

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130108663A1 (en) * 2007-09-14 2013-05-02 Vrije Universiteit Brussel Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and their use in vaccination
EP4011451A1 (en) * 2015-10-22 2022-06-15 ModernaTX, Inc. Metapneumovirus mrna vaccines
CA3040337A1 (en) * 2016-10-26 2018-05-03 Curevac Ag Lipid nanoparticle mrna vaccines

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016537978A (ja) * 2013-11-12 2016-12-08 ヴリジェ ユニヴェルシテ ブリュッセル Ｒｎａ転写ベクター及びその使用
JP2017513956A (ja) * 2014-04-23 2017-06-01 モデルナティーエックス， インコーポレイテッド 核酸ワクチン
WO2019141814A1 (en) * 2018-01-18 2019-07-25 Etherna Immunotherapies Nv Lipid nanoparticles

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"CD40 Ligand Preferentially Modulates Immune Response and Enhances Protection against Influenza Virus", THE JOURNAL OF IMMUNOLOGY, vol. 193(2), JPN6025006720, 2014, pages 722 - 734, ISSN: 0005531924 *
"Modulation of Regulatory T Cell Function by Monocyte-Derived Dendritic Cells Matured through Electro", THE JOURNAL OF IMMUNOLOGY, vol. 191(4), JPN6025006721, 2013, pages 1976 - 1983, ISSN: 0005531923 *
"NALT免疫システムのエイズ粘膜ワクチン開発への応用", 日本臨床免疫学会会誌, vol. 23(6), JPN6025006722, 2000, pages 579 - 581, ISSN: 0005664289 *
"Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1", AIDS, vol. 32, no. 17, JPN6025006724, 2018, pages 2533 - 2545, ISSN: 0005664287 *
"Preclinical evaluation of an mRNA HIV vaccine combining rationally selected antigenic sequences and", AIDS, vol. 31, no. 3, JPN6025006725, 2017, pages 321 - 332, ISSN: 0005664286 *
"経鼻ワクチンによる免疫誘導", 日鼻誌, vol. 51(1), JPN6025006723, 2012, pages 58 - 59, ISSN: 0005664288 *

Also Published As

Publication number Publication date
BR112022015666A2 (pt) 2022-09-27
CA3170239A1 (en) 2021-08-19
AU2021219304A1 (en) 2022-10-06
CN115443148B (zh) 2024-08-06
MX2022009943A (es) 2022-10-18
WO2021160881A9 (en) 2022-11-10
TW202144002A (zh) 2021-12-01
US20230071518A1 (en) 2023-03-09
WO2021160881A1 (en) 2021-08-19
IL295507A (en) 2022-10-01
EP4103226A1 (en) 2022-12-21
ZA202209779B (en) 2024-01-31
KR20230004447A (ko) 2023-01-06
CN115443148A (zh) 2022-12-06

Similar Documents

Publication Publication Date Title
JP2023518340A (ja) 鼻腔内ｍＲＮＡワクチン
US12390523B2 (en) Coronavirus vaccine
US11241493B2 (en) Coronavirus vaccine
EP4147717A1 (en) Coronavirus vaccine
Bai et al. A single vaccination of nucleoside-modified Rabies mRNA vaccine induces prolonged highly protective immune responses in mice
US20230105376A1 (en) Piv5-based coronavirus vaccines and methods of use thereof
US11730804B1 (en) Compositions and methods for the prevention and treatment of rabies virus infection
HK40085781A (en) Intranasal mrna vaccines
US20250032603A1 (en) Expression of the spike s glycoprotein of sars-cov-2 from avian paramyxovirus type 3 (apmv3)
Tamming Enhancing SARS-CoV-2 DNA Vaccines with CD40 Ligand and Lipid Nanoparticle Delivery
WO2023126343A1 (en) Mrna vaccine against variants of sars-cov-2
HK40090415A (en) Coronavirus vaccine
CN118632708A (zh) 基于piv5的冠状病毒疫苗及其使用方法

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20221005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250219

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250818